November 24, 2014 / 1:20 PM / 5 years ago

Merck buys rights to NewLink's experimental Ebola vaccine

Nov 24 (Reuters) - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp’s experimental Ebola vaccine.

Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.

Financial details were not disclosed.

The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug.

The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015. (Reporting by Vidya L Nathan in Bangalore; Editing by Siddharth Cavale)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below